📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-05 15:54
0 analysed today
FollowTelegram
0
Today
151,433
All-time analysed
43,376
Positive
6,732
Negative
92,513
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
₹0.22 Cr Net Profit for Biogen Pharmachem in Q1; Revenue Declines 71% YoY
Biogen Pharmachem reported a net profit of ₹0.22 crore for the quarter ended June 30, 2026, marking a recovery from a loss of ₹0.36 crore in the previous quarter (Q4 FY26). However, the company's revenue from operations witnessed a sharp 71.2% year-on-year decline, falling to ₹0.44 crore from ₹1.54 crore in Q1 FY26. The return to profitability was primarily driven by a significant reduction in total expenses, which dropped to ₹0.22 crore from ₹0.94 crore in the preceding quarter. Despite the profit, the absolute scale of operations remains extremely small for a company with a ₹28 crore market cap.
Confidence: HIGH
What changedThe company transitioned from a loss-making quarter to a marginally profitable one sequentially, while simultaneously experiencing a major contraction in its top-line revenue.
Why it mattersFor a micro-cap financial services firm, the shrinking revenue base (now just ₹0.44 cr per quarter) suggests a lack of business momentum and high vulnerability to even minor operational cost increases.
Revenue (Q1 FY27): ₹44.34 lacsNet Profit (Q1 FY27): ₹22.14 lacsRevenue Growth (YoY): -71.2%Revenue vs TTM Revenue: ~44%Paid-up Equity Capital: ₹105.30 cr
📅 Short termThe sequential turnaround to profit might offer some support to the stock price, but the substantial YoY revenue drop is likely to weigh on sentiment.
📈 Long termLimited; the company's extremely small scale and inconsistent revenue trajectory make it a high-risk entity with no clear structural growth path.
⚠ Risk flags
- Extremely low revenue base
- Significant YoY revenue contraction
- Penny stock volatility
- Trading significantly below face value
Key Highlights
Revenue from operations fell 71.2% YoY to ₹44.34 lacs (₹0.44 cr) from ₹154.28 lacs.
Net profit stood at ₹22.14 lacs (₹0.22 cr) compared to a loss of ₹35.88 lacs in the previous quarter.
Total expenses were reduced by 76.3% sequentially to ₹22.20 lacs from ₹93.70 lacs.
Paid-up equity share capital increased to ₹105.30 cr from ₹90.26 cr in the year-ago period.
Earnings Per Share (EPS) remained negligible at ₹0.00 for the quarter.
👀 What to Watch
Investors should monitor the company's ability to arrest the sharp decline in revenue, as the current profitability is solely due to cost-cutting rather than business growth.
Biogen Pharmachem Q1 FY27: Net Profit of ₹0.22 Cr on Revenue of ₹0.44 Cr
Biogen Pharmachem Industries reported a net profit of ₹22.14 lakhs for the quarter ended June 30, 2026, marking a recovery from a net loss of ₹35.88 lakhs in the preceding March quarter. However, revenue from operations declined 23% quarter-on-quarter to ₹44.34 lakhs and fell sharply by 71% compared to ₹154.28 lakhs in the year-ago period. The company's paid-up equity share capital increased to ₹105.30 Cr from ₹90.26 Cr. Despite the revenue drop, profitability was achieved through a significant reduction in total expenses, which fell to ₹22.20 lakhs from ₹93.70 lakhs in the previous quarter.
Confidence: HIGH
What changedThe company returned to profitability in Q1 FY27 after a loss in the previous quarter, primarily driven by aggressive cost-cutting as revenue continued to decline.
Why it mattersFor a micro-cap company with a market cap of just ₹28 Cr, the return to profit is a positive sign, but the 71% YoY revenue drop suggests significant business volatility or a shrinking core operation.
Revenue (Q1 FY27): ₹44.34 lakhsNet Profit (Q1 FY27): ₹22.14 lakhsQ1 Revenue vs TTM Revenue: 44.34%YoY Revenue Growth: -71.2%Equity Share Capital: ₹105.30 Cr
📅 Short termThe return to profit may provide a minor sentiment boost, but the low absolute revenue figures and penny-stock status (₹0.3) imply high volatility.
📈 Long termLimited. The company shows inconsistent revenue growth and operates at a very small scale relative to its equity base.
⚠ Risk flags
- Significant year-on-year revenue contraction
- Micro-cap liquidity risk
- Stock trading below face value
- High volatility in quarterly margins
Key Highlights
Net profit of ₹22.14 lakhs in Q1 FY27 vs a loss of ₹35.88 lakhs in Q4 FY26
Revenue from operations fell 71.2% year-on-year to ₹44.34 lakhs from ₹154.28 lakhs
Total expenses reduced by 76% quarter-on-quarter to ₹22.20 lakhs
Paid-up equity share capital increased by ₹15.04 Cr to ₹105.30 Cr during the quarter
Earnings Per Share (EPS) remained flat at ₹0.00 for the quarter
👀 What to Watch
Investors should monitor if the company can sustain profitability given the sharp decline in top-line revenue and watch for the specific deployment of the increased equity capital.
